Johnson & Johnson Warns Doctors of Doxil Cancer-Drug Shortage

Johnson & Johnson (JNJ.N) has cautioned doctors not to begin treatment with its Doxil cancer drug because of shortages of the medicine made by an outside manufacturer. The company had informed doctors last month about a potential shortage of the injectable medicine, made by a unit of German drugmaker Boehringer Ingelheim. In a "Dear Healthcare Provider" letter posted this week on the drug's website, www.doxil.com, J&J confirmed that a shortage indeed now exists and that new supplies of the medicine will not be shipped until late August. "Supplies may be intermittently available in the weeks thereafter," the letter said. "Until then, we advise that no new patients begin treatment with Doxil."

Back to news